Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have received an average rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $14.30.

A number of research analysts have issued reports on VNDA shares. Wall Street Zen downgraded Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Monday, April 20th. Finally, HC Wainwright reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Thursday, June 4th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Torren Management LLC bought a new position in shares of Vanda Pharmaceuticals during the 4th quarter valued at approximately $25,000. Russell Investments Group Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 5,328 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in shares of Vanda Pharmaceuticals by 3,010.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 10,055 shares during the period. Jain Global LLC purchased a new position in Vanda Pharmaceuticals in the fourth quarter valued at approximately $94,000. Finally, Quarry LP purchased a new position in Vanda Pharmaceuticals in the third quarter valued at approximately $53,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Stock Performance

VNDA stock opened at $5.44 on Friday. The company has a quick ratio of 2.15, a current ratio of 2.16 and a debt-to-equity ratio of 0.01. The firm has a market cap of $327.11 million, a PE ratio of -1.34 and a beta of 0.60. The business has a 50 day moving average of $6.11 and a 200-day moving average of $7.02. Vanda Pharmaceuticals has a 12-month low of $4.14 and a 12-month high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13). The business had revenue of $51.72 million for the quarter, compared to the consensus estimate of $54.98 million. Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%. As a group, sell-side analysts expect that Vanda Pharmaceuticals will post -2.2 earnings per share for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.